WHAT IS THE BrILliance CLINICAL RESEARCH STUDY?

If you have an advanced solid tumor, please know that you are not alone in your medical journey.

Currently, we are working on developing potential treatments for certain solid tumors. BrILliance is a clinical research study that aims to assess the safety, tolerability, and efficacy of a study drug in people who have advanced solid tumors.

Am I eligible?

What is the study treatment?

This treatment is an antibody-cytokine fusion protein. Antibodies are produced by your immune system to fight infections. Scientists can make antibodies in the laboratory for the treatment of many different diseases, including cancer. Cytokines are small proteins that control the growth and activity of other immune system cells. The study drug works by blocking PD-1, a receptor on immune cells that prevents them from destroying other cells, and by activating IL2, a cytokine that can trigger immune responses. Blocking PD-1 and activating immune cells through IL2 at the same time is expected to help immune cells attack cancer cells.

Once the study doctor confirms that you qualify, you will be assigned to Phase 1 or Phase 2 of the study. There is no placebo in this study, which means that all patients will receive the study drug. 

What can I expect if I participate?

participation is 100% voluntary

Study participation is 100% voluntary (your choice). You will receive information on what to expect, as well as your roles and responsibilities if you join the BrILliance study. You may leave the study at any time without it affecting your regular health care.

If you join the study, there are certain things you will be expected to do. This includes attending study visits and undergoing certain assessments and procedures, such as biopsies, MRI or CT scans, and heart imaging. The length of your treatment and number of study visits will depend on your response to the study drug.  

Reasonable travel costs (like fuel, bus/train tickets) and food costs will be refunded to you. The study team will discuss all of this with you.

How can I take part?

If you wish to take part in BrILliance, you can fill in a short pre-screener questionnaire to see if you may be eligible.

Am I eligible?

What else should I know?

This study will use an investigational drug product, R10597, whose safety and efficacy has not been fully evaluated by regulatory authorities; therefore, there remain risks associated with its use. If you qualify and choose to participate, you will be provided with an Informed Consent Form that explains any possible risks and side effects. It is also possible that the study drug may affect you in unknown ways. Your health and safety are our top priorities and will be closely monitored throughout your participation.

You may benefit from additional check-ups on top of your regular care and have access to cancer specialists. There is no guarantee that you will receive a medical benefit from participating in this study. Your condition may get better, stay the same, or may even get worse. You are free to withdraw from the study for any reason and at any time.